30 Aug

Glaukos Stock Rose 40.3% on August 29

WRITTEN BY Margaret Patrick

Share price movements

Glaukos’ (GKOS) share price rose ~40.3% and closed at $62.86 on August 29. The increase was a reaction to the news from Novartis’ (NVS) Alcon business unit about the immediate and voluntary withdrawal of its CyPass Micro-Stent across the world on June 29.

In July 2016, the CyPass Micro-Stent was approved by the FDA to be used along with cataract surgery for patients suffering from mild-to-moderate primary open-angle glaucoma. However, safety data from the COMPASS-XT trial evaluating five-year post-surgery data highlighted the loss of endothelial cells in patients using the CyPass Micro-Stent compared to patients only undergoing cataract surgery. Alcon asked surgeons not to implant anymore of the stents and return used devices to the company.

The reduced competition for Glaukos’ glaucoma devices caused Robbie Marcus, a JPMorgan Chase analyst, to increase the company’s target price to $75, which implies an upside potential of ~19.3%—compared to the company’s last closing price. In the second quarter, Glaukos reported revenues close to $43.16 million—a rise of 4.6% year-over-year. The company beat the revenue estimate by $2.67 million but missed the EPS estimate by $-0.03. Glaukos updated its fiscal 2018 revenue guidance range from $160 million–$165 million to $162 million–$166 million in its second-quarter conference call.

Glaukos Stock Rose 40.3% on August 29

Analysts’ recommendations for Glaukos

Of the eight analysts covering Glaukos in August, four analysts recommended a “strong buy,” two recommended a “buy,” and two recommended a “hold.” Analysts have projected Glaukos’ 12-month consensus target price to be ~$60.71, which would be a decline of ~3.4% over the company’s last closing price of $62.86.

Analysts’ recommendations for peers

Of the 26 analysts covering Novartis (NVS) in August, ~50% recommended a “buy,” ~70.8% of the 24 analysts covering Allergan (AGN) recommended a “buy,” and 78.9% of the 19 analysts covering Abbott Laboratories (ABT) recommended a “buy.”

Latest articles

Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.

The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.

Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.

Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.

14 Jun

IEA Again Slashes Its Oil Demand Growth Estimate

WRITTEN BY Rabindra Samanta

As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.

Amazon is discontinuing its Amazon Restaurants service, which has been delivering food for restaurants in parts of the United States. Amazon Restaurants launched in the United States in 2015 and entered the British market the following year. However, it met strong opposition in the British market.

172.31.16.229